Developing innovative peptide drugs to fight specialist diseases

ImmuPharma is an evolving speciality biopharmaceutical company.

We are developing an innovative portfolio of novel peptide-based therapeutic drugs, or Bio-drugs, focusing on Autoimmunity/Inflammation and Anti-Infectives.

Unlocking value through licensing, partnering and collaborations.

Creating near term shareholder value with our lead asset, Lupuzor™ as it moves through its Phase 2/3 adaptive study.

Our pipeline

Lupuzor™ Lupus*
P140 CIDP*
P140 other indications

*Phase 2/3 adaptive trial becomes a pivotal trial for filing

BioAMB Fungal infections
BioCIN Bacterial infections

Key progress

Share Price

Market Cap

Market Commentary